Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…
Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)
This guidance has been updated and replaced by NICE technology appraisal guidance 433.
Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults
Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears
Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)
This guidance has been updated and replaced by NICE technology appraisal guidance 458.
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults
This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C
This guidance has been updated and replaced by NICE technology appraisal guidance 476.
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults
The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...
Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...
NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…
Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism
This guidance has been replaced by NICE guideline NG17.
This guidance has been replaced by NICE guideline NG17.
Evidence-based recommendations on aflibercept (Eylea) for treating diabetic macular oedema
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema
Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis
NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at email@example.com or 01932 842100 for details.
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia
This guidance has been updated and replaced by NICE technology appraisal guidance 427.
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma